Menora Mivtachim Holdings LTD. Invests $82.92 Million in Merck & Co., Inc. (NYSE:MRK)

Share on StockTwits

Menora Mivtachim Holdings LTD. bought a new position in Merck & Co., Inc. (NYSE:MRK) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 988,870 shares of the company’s stock, valued at approximately $82,917,000. Merck & Co., Inc. makes up about 2.2% of Menora Mivtachim Holdings LTD.’s portfolio, making the stock its 20th biggest position.

Other institutional investors and hedge funds have also recently modified their holdings of the company. JJJ Advisors Inc. acquired a new position in shares of Merck & Co., Inc. in the 2nd quarter worth approximately $27,000. PRW Wealth Management LLC bought a new stake in shares of Merck & Co., Inc. in the 4th quarter worth approximately $41,000. Aspire Private Capital LLC bought a new stake in shares of Merck & Co., Inc. in the 4th quarter worth approximately $55,000. Thor Advisors LLC bought a new stake in shares of Merck & Co., Inc. in the 1st quarter worth approximately $69,000. Finally, Contravisory Investment Management Inc. lifted its holdings in shares of Merck & Co., Inc. by 19.7% in the 2nd quarter. Contravisory Investment Management Inc. now owns 858 shares of the company’s stock worth $72,000 after purchasing an additional 141 shares during the last quarter. Institutional investors own 75.34% of the company’s stock.

Merck & Co., Inc. stock traded down $0.28 during mid-day trading on Thursday, hitting $83.12. 221,051 shares of the company’s stock traded hands, compared to its average volume of 9,473,427. The company has a 50 day moving average price of $83.37. The company has a debt-to-equity ratio of 0.82, a quick ratio of 0.92 and a current ratio of 1.21. The firm has a market cap of $219.45 billion, a P/E ratio of 19.16, a PEG ratio of 1.74 and a beta of 0.56. Merck & Co., Inc. has a one year low of $66.10 and a one year high of $87.07.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, July 30th. The company reported $1.30 earnings per share for the quarter, beating the consensus estimate of $1.16 by $0.14. The firm had revenue of $11.76 billion for the quarter, compared to the consensus estimate of $10.94 billion. Merck & Co., Inc. had a return on equity of 43.34% and a net margin of 21.10%. The firm’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.06 EPS. Sell-side analysts forecast that Merck & Co., Inc. will post 4.91 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, October 7th. Shareholders of record on Monday, September 16th will be paid a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 2.65%. The ex-dividend date of this dividend is Friday, September 13th. Merck & Co., Inc.’s payout ratio is currently 50.69%.

Several analysts recently issued reports on MRK shares. UBS Group raised their price target on Merck & Co., Inc. from $87.00 to $88.00 and gave the stock a “buy” rating in a report on Thursday, May 2nd. Credit Suisse Group reissued a “buy” rating and issued a $95.00 price target on shares of Merck & Co., Inc. in a report on Wednesday, August 7th. Citigroup raised their price target on Merck & Co., Inc. from $84.00 to $95.00 and gave the stock a “buy” rating in a report on Friday, June 21st. They noted that the move was a valuation call. Morgan Stanley raised their price target on Merck & Co., Inc. from $84.00 to $90.00 and gave the stock an “overweight” rating in a report on Friday, June 21st. Finally, Atlantic Securities raised Merck & Co., Inc. from a “neutral” rating to an “overweight” rating in a report on Monday, May 13th. They noted that the move was a valuation call. Three analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $91.07.

In other Merck & Co., Inc. news, EVP Richard R. Deluca sold 6,427 shares of Merck & Co., Inc. stock in a transaction on Friday, August 9th. The stock was sold at an average price of $85.09, for a total transaction of $546,873.43. Following the sale, the executive vice president now owns 103,223 shares of the company’s stock, valued at approximately $8,783,245.07. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Robert M. Davis sold 216,718 shares of Merck & Co., Inc. stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $85.43, for a total value of $18,514,218.74. Following the sale, the chief financial officer now directly owns 354,378 shares in the company, valued at approximately $30,274,512.54. The disclosure for this sale can be found here. 0.27% of the stock is owned by insiders.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Recommended Story: How is inflation measured?

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.